Review of Edison Bicudo, \u3ci\u3ePharmaceutical Research, Democracy and Conspiracy: International Clinical Trials in Local Medical Institutions\u3c/i\u3e by Abadie, Roberto
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Sociology Department, Faculty Publications Sociology, Department of
6-2015
Review of Edison Bicudo, Pharmaceutical Research,
Democracy and Conspiracy: International Clinical
Trials in Local Medical Institutions
Roberto Abadie
University of Nebraska-Lincoln, rabadie2@unl.edu
Follow this and additional works at: http://digitalcommons.unl.edu/sociologyfacpub
Part of the Bioethics and Medical Ethics Commons, Family, Life Course, and Society Commons,
Pharmacoeconomics and Pharmaceutical Economics Commons, Pharmacy Administration, Policy
and Regulation Commons, and the Social Psychology and Interaction Commons
This Article is brought to you for free and open access by the Sociology, Department of at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Sociology Department, Faculty Publications by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.
Abadie, Roberto, "Review of Edison Bicudo, Pharmaceutical Research, Democracy and Conspiracy: International Clinical Trials in Local
Medical Institutions" (2015). Sociology Department, Faculty Publications. 578.
http://digitalcommons.unl.edu/sociologyfacpub/578
A b a d i e  i n  M e d  A n t h r o  Q t r ly  ( 2 0 1 5 ) ,  r e v i e w  o f  B i c u d o       1
Published in Medical Anthropology Quarterly 29:2 (June 2015), pp b1-b3.
doi 10.1111/maq.12169 
Copyright © 2014 by the American Anthropological Association.  
Published by John Wiley & Sons, Inc. Used by permission.
Published 23 December 2014.
BOOK REVIEW
Pharmaceutical Research, Democracy and 
Conspiracy: International Clinical Trials  
in Local Medical Institutions  
by Edison Bicudo
(Surrey, UK: Gower, 2014), 175 pp. 
Reviewed by Roberto Abadie 
University of Nebraska, Lincoln 
In late 2003, Dan Markingson, a young man experiencing an acute 
psychotic episode, went to his doctor at the University of Minnesota 
in search of treatment for his symptoms; he was involuntarily com-
mitted and ordered by the court to follow a treatment prescribed by 
his psychiatrist, Dr. Stephen Olson. Instead of treating him, Olson en-
rolled Markingson in an AstraZeneca-sponsored trial for an antipsy-
chotic drug, for which Olson’s university received $15,600—and more 
than $327,000 for all patients recruited. 
Markingson’s mental health did not improve on this drug but Dr. 
Olson kept insisting that everything was fine. For months, Marking-
son’s mother fought to take her son out of the trial, telling Dr. Olson 
that her son was, in fact, deteriorating and that she feared he would 
commit suicide. Yet, he was kept in the study, went into a psychotic 
episode, and committed suicide in May 2004. Neither the University 
of Minnesota nor the state of Minnesota has properly investigated the 
suicide, the ethics of the study, or the potential conflicts of interests, 
and nobody involved has been held accountable. Dr. Olson, the prin-
cipal investigator of the study, remains in his position at the Univer-
sity of Minnesota (Elliott 2013). 
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This episode is far from unique. Carl Elliott, who first drew at-
tention to this study at the University of Minnesota, has recently un-
covered the recruitment of homeless psychiatric patients into clini-
cal trials in Philadelphia. This recruiting practice was pioneered by 
Eli Lily, the Midwest pharmaceutical giant, who years ago started 
targeting vulnerable populations through aggressively recruiting in 
soup kitchens and homeless shelters. In a “no-guinea-pig-left-behind” 
drive, even undocumented Latinos have been recruited as trial sub-
jects in Florida. 
The pharmaceutical industry is—along with the financial and weap-
ons industries—one of the most globalized and profitable business do-
mains. But they wouldn’t make any profits if they weren’t able to re-
cruit research subjects to test an increasing number of drugs. This 
global trial economy creates its own assemblages of clinical trials, of-
ten run by hired contract research organizations (CROs), who fight 
among each other in a rat-race competition, promising quick and ef-
fective trials; at the same time, enterprising countries, hospitals, and 
doctors jump on the drug trial economy bandwagon by promising 
quick, endless access to a large pool of research subjects, with little 
or no ethical oversight. 
This is the world that Edison Bicudo has examined in Pharma-
ceutical Research, Democracy and Conspiracy. Based on dozens of in-
terviews with pharmaceutical company representatives, CRO man-
agers, clinical trial recruiters, physicians conducting trials, as well as 
staff and administrators for drug trial sites, the book aims to explore 
“the new relationships between global and local actors” (p. 6). Field-
work was conducted in five countries: the UK, Spain, France, Brazil, 
and South Africa. The first three are home to the largest number of 
pharmaceutical companies, or “sponsors,” and their CROs, while the 
last two accommodate the largest number of hired physicians and 
patients/subjects. 
The focus of the study is on the “initial stages, in which studies are 
yet not running, investigators not yet dealing with clinical matters and 
research with subjects not yet undergoing the study procedures” (p. 
7). Bicudo justifies this choice with the reasoning that it allows him 
“to surprise the trials industry forging the social chains with which 
clinical trials are made not only scientifically and legally feasible but 
also socially and culturally possible” (p. 7). One potential pitfall of this 
choice is that we never learn about subjects’ experiences as research 
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subjects. Bicudo draws attention to what he calls “mediational ac-
tions,” which he argues are instrumental to the success of the clinical 
trials enterprise because they enable the pharmaceutical industry to 
navigate the translation from the global to the local contexts. 
While this is an important topic, numerous authors before Bicudo 
have analyzed the multiple logics or rationalities behind the global 
clinical trial enterprise and their articulation in local contexts. And de-
spite the author’s attempts that apply Habermas’s theory of commu-
nicative action (Habermas 1984), the author fails to provide any se-
rious insights other than the idea that local contexts matter. Perhaps 
the most interesting section is focused on the privatization of clinical 
trials that are conducted in state or publicly funded institutions. As a 
result of such privatization, according to the author, the trials industry 
is determining research pathways to be taken by certain medical insti-
tutions, which are increasingly playing the role of research sites. The 
initiation of dozens of studies on a certain disease, the mobilization 
of hundreds of caregivers in several countries and the subsequent re-
cruitment of thousands of patients all over the world derive from tech-
nical decisions taken in headquarters of global companies whose staff 
may be lacking appropriate knowledge about national needs. (p. 46) 
Bicudo seems worried about this trend, wondering “whether global 
clinical trials can contribute to the construction and consolidation of 
democratic societies” (p. 160). He notes that state regulatory agencies 
continue to depend on fees received from the pharmaceutical indus-
try, thus compromising “their independence and willingness to fore-
stall political abuses” (p. 161). 
In the end, he argues, the solution is to “enhance the role of insti-
tutions and legitimate law” (p. 161). Of course, there is nothing wrong 
with this prescription, in theory, but in practice there is. Bicudo ne-
glects how the pharmaceutical industry uses their immense financial 
power to buy political influence, allowing them to get legislation or 
regulation they want approved while blocking those initiatives they 
perceive as harming their bottom line. 
Anthropologists and social scientists have done quite a bit of work 
unmasking pharmaceutical practices in recent years, from the work of 
drug representatives, to the globalization of clinical trials, but much 
more work needs to be done in the area of pharmaceutical regulation. 
Specifically, we need to explore the role of pharmaceutical lobbying—
not only the financing of political campaigns but also how it shapes 
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legislative outcomes. We should also study how Big Pharma uses its 
financial and political power to influence the Food and Drug Adminis-
tration’s drug approval process. If the social sciences want to remain 
vital and viable they won’t be able to avoid tackling the relationship 
between the pharmaceutical industry —and corporations in general—
and our political process, and what it all means for our citizens and 
the quality of our democracy. 
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